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1. Introduction
Major histocompatibility complex class II mole-
cules (MHC II) have developed a particular tra⁄ck-
ing pathway, which allows them to load antigenic
peptides generated in the endosomal/lysosomal sys-
tem. Following the original description of MHC II
associated invariant chain (Ii) in 1983 [1,2], evidence
has accumulated demonstrating that its binding to
MHC II K and L chains is crucial at several steps
of MHC II biogenesis and function [3]. Despite the
small size of Ii, this protein comprises an impressive
and still growing number of functions (see Table 1).
Here, we will review the di¡erent roles of Ii, while
following the journey of nascent MHC II complexes
through the cell. Special attention will be given to the
molecular events taking place in the endoplasmic re-
ticulum (ER), during the transport to and within the
endocytic pathway.
Newly synthesized MHC II K and L chains asso-
ciate with Ii in the ER. The resulting nonameric
complexes (KLIi)3 exit from the ER, tra⁄c through
the Golgi and are then directed towards the endo-
cytic pathway. There, Ii is progressively degraded
until only an Ii derived peptide called CLIP (for
CLass II associated Invariant chain derived Peptides)
remains associated with MHC II. CLIP is then ex-
changed for an antigenic peptide in a reaction cata-
lyzed by the non-classical MHC II, human leukocyte
antigen (HLA)-DM and -DO in human (H2-DM
and -DO in mouse according to the new nomencla-
ture [4]). The resulting mature MHC II^peptide com-
plexes are ultimately released to the cell surface for
recognition by CD4 Th cells.
2. Within the endoplasmic reticulum
2.1. Structure of the Ii chain
Ii chain is a non-polymorphic type II integral
membrane protein, where the N-terminus constitutes
a short cytoplasmic tail of 28 amino acids (aa) (Fig.
1). Alternative initiation of translation and di¡eren-
tial splicing of the transcription products generate
four di¡erent isoforms in human (p33, p35, p41
and p43) [5]. Because of its predominance we will
mainly focus on the 216 aa long isoform, which is
referred to as p33 in human (and often termed p31 in
mouse) according to its apparent molecular mass [1].
Ii assembles to homotrimers immediately after syn-
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thesis [6^8]. The region responsible for its self-asso-
ciation was mapped by analysis of deletion mutants
of Ii to residues 163^183 [9,10]. NMR analysis of
proteolytic fragments of Ii and of recombinant solu-
ble Ii con¢rmed this result by identifying a highly
structured, protease resistant luminal domain (aa
118^192) [11^13] as the trimerization domain
(Fig. 1). This part of Ii is organized in an K-helical
coiled-coil structure forming a sca¡old suitable for
simultaneous interaction with three KL heterodimers
[12]. Indirect evidence suggests that the trans-
membrane region might also contribute to stable
homotrimer formation [14]. Moreover, a patch of
hydrophilic residues (aa 47, 49 and 50) situated with-
in the transmembrane domain of Ii near the luminal
interface appears to be required for Ii trimerization
[15].
2.2. Association with MHC II
Two disordered £exible domains (aa 72^110 and
aa 187^216) £ank the Ii trimerization domain
(Fig. 1). The N-terminal unfolded Ii domain was
described to acquire a signi¢cantly ordered structure
upon complex formation with HLA-DR1 [16]. This
domain contains the CLIP region (Fig. 1), which has
been identi¢ed by means of various deletion and
truncation mutants of Ii as necessary and su⁄cient
for its interaction with MHC II [9,17]. This CLIP
region corresponds to a nested set of peptides derived
from Ii (aa 81^104) and eluted from MHC II of
human and murine B cell lines defective for antigen
presentation due to their lack of HLA-DM/H2-DM
[18^20]. The determination of the crystal structure of
a HLA-DR3^CLIP complex showed that CLIP
Fig. 1. Structural features of the p33 invariant chain. An alignment of the primary structure of the human and mouse invariant chain
is presented. See text for detailed explanation.
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binds in the MHC II groove in a way highly re-
sembling the binding of antigenic peptide, with resi-
dues 87^101 (core CLIP) occupying the groove and
both extremities protruding out of the binding site
[21].
Interestingly, Ii is able to bind to all MHC II al-
lelic products despite important variations in their
a⁄nity for CLIP [22,23], suggesting that other re-
gions than CLIP enforce the association of intact Ii
with MHC II. Indeed, three additional luminal re-
gions of Ii have been shown to contribute to the
promiscuous binding of Ii to MHC II via contacts
outside the polymorphic antigenic groove. They in-
clude a region immediately N-terminal of core CLIP
(81^89) [24^27], a region C-terminal to core CLIP
(103^118) [25,26,28] and a region located in the
C-terminal trimerization domain (118^192) [13].
The two £anking regions could position core CLIP
just above or in the peptide binding groove, thus
providing the necessary means for e⁄cient MHC II
assembly. Indirect evidence suggested that further
contacts between MHC II and Ii could take place
within the transmembrane domains [14,29]. Finally,
a recent study using peptide loaded MHC II, Ii trun-
cation mutants and Ii/transferrin receptor (TfR) chi-
mera indicated that Ii and MHC II transmembrane
domains signi¢cantly contribute to the formation of
KLIi complexes [30].
2.3. Chaperoning MHC II
Ii chain transiently associates with MHC II chains,
favors their proper folding and therefore acts as a
speci¢c MHC II chaperone. Newly synthesized K
and L subunits rapidly pass a transient stage, when
they form high molecular mass aggregates, from
which they are eventually rescued by Ii [31,32]. Indi-
vidual pairs of KL chains successively bind to a scaf-
fold of an Ii trimer [6,33]. Association of the ER
resident chaperone calnexin with each of the three
subunits stabilizes the assembling complex until com-
pletion of the (KLIi)3 nonamer [34,35]. Other chap-
erone molecules described to interact with MHC II
chains in the ER include BiP (grp78) [31,36] and
grp94 and Erp72 [37], but it is not established
whether this constituted the physiological situation
or was due to the absence of Ii in the studied cell
types.
2.4. Prevention of premature peptide binding
The requirement of Ii for the formation of func-
tional KL dimers strongly depends on the MHC II
allele considered [38,39] most likely because of di¡er-
ences in the intrinsic stability of KL dimers [40]. Im-
portantly, Ii association with MHC II prevents nas-
cent MHC II to bind unfolded polypeptides or short
peptides present in the ER. Binding of peptide and Ii
were shown to be mutually exclusive in di¡erent ex-
perimental setups [33,41,42]. Nevertheless, endoge-
nous antigen presentation by MHC II has been
documented in some instances (for review see [3]).
It has been recently established that presentation of
an endogenous cytoplasmic antigen by MHC II re-
quires proteasome processing and translocation into
endosomes [43]. On the other hand, signi¢cant
amounts of KL dimers were found to stably bind a
heterogeneous, but speci¢c set of intact polypeptides
of 20^200 kDa in the ER of Ii negative HeLa cells
transfected with MHC II chains [44,45]. Interest-
ingly, dendritic cells (DCs) from Ii de¢cient H-2k
mice also displayed mature MHC II complexes of
varying molecular mass up to 120 kDa [39]. This
phenomenon was not observed in B cells of Ii de¢-
cient mice [38], which could re£ect cell type speci¢c
di¡erences in the regulation of MHC II maturation
(see below).
2.5. Egress from the ER
The study of Ii de¢cient mice allowed to establish
Table 1
Summary of Ii functions
Ii functions Localization
Chaperone for MHC II K and L chains ER
Inhibition of peptide binding to
MHC II
ER, Golgi and
endosomes
Egress of MHC II from the ER ER/Golgi interface
Targeting to the endocytic pathway
of MHC II
Golgi/EE interface
Endocytosis of KLIi complexes Plasma membrane
Induction of large vacuoles/MVB Endosomal pathway
Modulation of proteolytic enzymes Endosomal pathway
Retention of KLIi and KLIi fragments Endosomal pathway
Protection of H2-DM from degradation Endosomal pathway
Promoting di¡erentiation of immature
B cells
Unknown
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another important function of Ii, i.e. promoting e⁄-
cient egress of MHC II from the ER. Ii helps MHC
II to pass the ER quality control system, which al-
lows only correctly assembled complexes to proceed
to the Golgi. MHC II molecules from splenic B cells
of Ii de¢cient mice exhibited defective post-ER trans-
port resulting in reduced levels of MHC II surface
expression, regardless of their capacity to assemble in
the absence of Ii [38,46^48], demonstrating the role
of Ii in MHC II transport out of the ER. Use of Ii
truncation mutants and peptides (CLIP or antigenic
peptides) covalently linked to the MHC II L chain
[49,50] showed that occupancy of the MHC II bind-
ing groove in the ER was su⁄cient to promote e⁄-
cient tra⁄cking of nascent MHC II to the Golgi
complex. However, this requirement also seemed to
be cell type and allele dependent [39].
3. En route to the endocytic pathway
3.1. Targeting motifs
Another major function of Ii is to ensure the tar-
geting of newly synthesized MHC II to the endocytic
pathway, where the complexes can meet antigenic
peptides. Transport steps which deviate from the
constitutive secretory pathway require structural mo-
tifs present in the cytoplasmic tails of tra⁄cking
membrane proteins (for review see [51]). The signals
mediating the sorting of KLIi complexes to the endo-
cytic pathway were mapped to the N-terminal cyto-
plasmic domain of Ii [52^54]. Ii deleted of its cyto-
plasmic tail failed to dissociate from MHC II dimers
and KLIi complexes were expressed at the plasma
membrane [52,55]. By means of Ii mutants and chi-
mera molecules, the endosomal localization signals
were identi¢ed as two independent motifs containing
two adjacent large hydrophobic non-aromatic resi-
dues at positions Leu7/Ile8 and Pro15/Met16/Leu17
in the Ii cytoplasmic tail [56^58] (see Fig. 1). NMR
analysis of a synthetic peptide corresponding to res-
idues 1^27 of human Ii indicated that the membrane
distal motif is situated within a nascent helix, while
the membrane proximal motif is part of a type 1 L
turn [59]. Mutational analysis revealed the impor-
tance of the residues located in spatial proximity
for e⁄cient targeting to endosomes, suggesting that
the motifs are recognized as part of a larger second-
ary structure [59,60]. The same signals also promote
rapid internalization via clathrin coated pits of the
plasma membrane [57,61]. By analyzing Ii-TfR chi-
meras in a quantitative internalization and transport
to lysosomes assay Kang et al. reported that the two
cytoplasmic di-leucine based signals were found im-
portant for lysosomal targeting. However, the
Met16/Leu17 signal was less e⁄cient for endocytosis
[62]. This is consistent with results obtained in polar-
ized MDCK cells, where basolateral sorting of Ii was
mainly dependent on the membrane proximal motif
in contrast to internalization, which was indepen-
dently mediated by both signals [63]. A second study
carried out in the same cell type mapped basolateral
sorting information to both leucine based signals and
to residues aa 20^30 of the cytoplasmic tail of Ii [64].
Several studies stressed the necessity of the Ii
transmembrane domain for e⁄cient delivery of
MHC II complexes to the endocytic pathway
[57,58]. Detailed mutational analysis of the Ii trans-
membrane domain identi¢ed two regions that were
su⁄cient to confer lysosomal targeting on a reporter
molecule without a¡ecting its internalization rate
[62]. Interestingly, the targeting function of Ii was
found to depend on its capacity to form homotrimers
[65,66]. Arneson et al. analyzed the intracellular
transport of complexes formed by intact Ii and/or
Ii mutants lacking the endosomal localization signals
(v2^17) in L cell transfectants expressing MHC II.
Their results established that a single Ii cytoplasmic
domain present in a heterotrimer was su⁄cient to
function as an internalization signal at the cell sur-
face, but that homotrimerization of Ii was required
for e⁄cient targeting to endosomal compartments
[65].
It has to be kept in mind that the sorting of MHC
II molecules does not entirely depend on Ii. The cy-
toplasmic tails of both MHC II chains and especially
a leucine based motif in the L chain are necessary for
correct internalization and thus for recycling of ma-
ture MHC II [67^69]. However, the ultimate step of
MHC II transport from lysosomes to the cell surface
rather depends on stable peptide binding than on the
cytosolic domains of the K and L chains [70].
Ii was further described to associate with the non-
classical MHC II molecule H2-DM/HLA-DM and to
direct it to the endocytic compartments containing
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MHC II [71^73]. H2-DM/HLA-DM are needed at
this location to ensure e⁄cient peptide loading
onto MHC II. However, these non-classical MHC
II molecules do not need Ii to reach their ¢nal desti-
nation. The cytoplasmic tail of the H2-DM and
HLA-DM L chain contains a tyrosine based sorting
signal, which ensures proper endosomal targeting
and rapid internalization from the cell surface in
the absence of Ii [72,73].
3.2. Which route, which entry door?
The actual route by which MHC II enter the en-
docytic pathway is an important determinant for
their function in antigen presentation, as it in£uences
the availability of di¡erent substrates for loading on
MHC II and the environment for peptide binding,
determining the nature of the material presented to
T cells. Morphological and biochemical approaches
indicate a direct transfer of MHC II molecules from
the TGN to endocytic compartments in many di¡er-
ent cell types [29,74^79]. However, surface expression
of newly synthesized KLIi complexes followed by
rapid internalization and access to the endosomal
pathway has also been documented [61,80]. The im-
portance of this indirect pathway depends very much
on the activation state and cell type studied. In hu-
man DCs and monocytes the majority of newly syn-
thesized MHC II complexes follow the itinerary via
the cell surface [81].
The entry point of KLIi complexes into the endo-
cytic pathway remained controversial for a long time.
Several studies indicate that KLIi gain access to the
endocytic pathway via early endosomes (EE)/sorting
endosomes, since KLIi complexes were transiently de-
tected in TfR positive EE before reaching late endo-
cytic compartments [82^85]. Two recent studies
showed by functionally ablating EE that this com-
partment was required for MHC II transport to pep-
tide loading compartments [86,87]. Thus, regardless
if nascent KLIi are directly sorted from the TGN to
the endocytic pathway or via the cell surface, EE
constitute the key compartment for the passage of
all MHC II complexes.
3.3. Which transport machinery is recruited by Ii?
A related issue that remains controversial concerns
the cytosolic machinery involved in the sorting of
KLIi at the trans-Golgi network (TGN) level. Di¡er-
ent cytosolic coat complexes are involved in TGN-
endosomal sorting through their interaction with ty-
rosine or di-leucine based signals. AP-1 (and clath-
rin) would determine the transport of mannose 6-
phosphate receptor (M6PR) to endosomes via di-leu-
cine motifs [88], whereas AP-3 was proposed to me-
diate direct transport of lysosomal resident proteins
to lysosomes [89]. Both represent potential candi-
dates in mediating KLIi transport to endosomes.
Overexpression of Ii allowed the recruitment of
AP-1 in a reconstituted cellular system in vitro [90].
Moreover, AP-1 and AP-2 were capable of interact-
ing in vitro with the di-leucine based motifs of Ii
cytoplasmic tail [91,92]. However, the capacity of Ii
to bind and even to recruit AP-1 does not prove that
KLIi are actually transported in AP-1 clathrin coated
vesicles. Indeed, opposite conclusions were obtained,
when the role of clathrin coated vesicles (CCVs) in
MHC II tra⁄cking was tested using a dominant neg-
ative mutant of clathrin, referred to as the hub frag-
ment. Co-expression of hubs and KLIi complexes by
transient transfection in mammalian cells caused cell
surface accumulation of KLIi complexes [93], demon-
strating that surface KLIi is endocytosed through
CCVs. Similar conclusions were drawn from a study
using a dominant negative mutant of dynamin [94].
Accumulation of hubs to inhibitory concentrations
before induction of KLIi expression did not a¡ect
direct delivery of KLIi complexes to endosomes, in-
dicating that this step occurred independently of
CCVs, in contrast to the transport of HLA-DM to
lysosomes, which was blocked in the same conditions
[93]. B lymphoblasts derived from patients su¡ering
from an enzymatic defect termed I-cell disease, pos-
sess a M6PR independent targeting pathway for ly-
sosomal enzymes. Analysis of the transport of MHC
II in such cells indicated that MHC II complexes can
be transported from the TGN to the endocytic com-
partments in vesicles lacking clathrin and M6PR [95].
Murine and human B cells with selectively inacti-
vated EE accumulated KLIi complexes in transport
vesicles lacking both M6PR and AP-1, further sug-
gesting that MHC II use an AP-1 independent trans-
port pathway to reach endosomes [86]. The analysis
of AP-1 de¢cient mice would have been a decisive
tool to address this controversy but for the embry-
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onic lethality of mice carrying a disruption of the
W1A- or Q-adaptin gene [96,97]. Analysis of MHC
II tra⁄cking and maturation in human and murine
cells de¢cient for the AP-3 complex revealed no sig-
ni¢cant alteration in the kinetics of tra⁄cking and
maturation of MHC II, indicating that AP-3 is not
essential for normal transport of MHC II [98,99].The
recent description of a novel family of ubiquitous
coat proteins termed GGAs, potentially involved in
TGN to EE transport [100], opens the question of
their possible involvement in the tra⁄cking of MHC
II.
Protein phosphorylation has been shown to posi-
tively regulate the recognition of leucine based endo-
somal targeting signals (see for instance [101]). Inter-
estingly, in a wide variety of human antigen
presenting cells (APCs), the Ii p35 isoform is phos-
phorylated on a serine residue in its cytosolic do-
main, probably by a member of the PKC family of
serine/threonine kinases [102,103]. Stimulation of
PKC activity by PMA signi¢cantly enhanced kinetics
of Ii proteolysis and generation of SDS-stable MHC
II complexes [104]. In addition, expression of an Ii-
phosphorylation mutant resulted in impaired degra-
dation of Ii and tra⁄cking of MHC II [104]. In con-
trast, in mouse cells exposed to PMA, Ii degradation
and MHC II maturation were enhanced and no
phosphorylation of Iip33 was observed [105], possi-
bly re£ecting the absence of the Iip35 isoform in
mouse. Finally, brefeldin A and aluminum £uoride
a¡ected the intracellular transport of MHC II, sug-
gesting that ADP-ribosylation factor and heterotri-
meric G proteins are involved in MHC II tra⁄cking
[79].
4. Within the endocytic pathway
4.1. Degradation events
Two degradation processes have to take place in a
coordinated manner in the endocytic pathway to
produce mature, peptide loaded MHC II. The Ii
chain needs to be cleaved to provide peptide-recep-
tive MHC II and antigenic peptides have to be pro-
duced by proteolysis of antigens. In the past years,
numerous studies aimed at identifying the players
involved in these proteolytic events.
Several proteases play a role in the stepwise deg-
radation of Ii (reviewed in [106] [107]). First, Ii is
cleaved to generate Iip22 (or LIP) and then Iip10
(or SLIP) by enzymes, which remain to be identi¢ed.
Amongst them, the asparaginyl endopeptidase (AEP)
is an attractive candidate for the ¢rst steps of Ii
degradation as indirectly suggested by a recent study
[108]. A cystatin homologue produced by a parasite
was able to inhibit both AEP activity and lysosomal
degradation of Ii. However, the involvement of
AEP in the ¢rst steps of Ii degradation has yet to
be formally demonstrated. The contributing enzymes
are expected to be leupeptin insensitive, since cells
exposed to this broad spectrum cysteine protease
inhibitor tended to accumulate both Iip22 and
Iip10, but not intact Ii. Biochemical and genetic
evidence indicates that cathepsins B, D, S, L and F
are not involved in the formation of Iip10 (see [109]).
More information has been obtained regarding
the conversion of Iip10 to CLIP. The major enzyme
involved appears to be cathepsin S as demonstrated
by the use of speci¢c inhibitors and of knockout
mice [110^114]. However, depending on the type
of APC considered, other enzymes can also perform
this conversion. In thymic epithelial cells, which do
not express cathepsin S, production of CLIP was
achieved by cathepsin L [115]. Moreover, macro-
phages from mice de¢cient for both cathepsins S
and L appeared fully functional concerning Ii pro-
cessing and peptide loading due to the action of
cathepsin F [116].
Of note, very little information has been obtained
about the degradation of antigen leading to the pro-
duction of peptides within the endocytic pathway in
vivo. Antigen processing would involve a thiol reduc-
tase activity, proteases with preferences for polar,
charged or hydrophobic residues, as well as endo-
and exo-peptidases (see [107]).
4.2. Modulation of proteolysis
Ii can modulate enzymatic activities and we will
see later that the enzymatic activities driving Ii deg-
radation can also be regulated. A non-covalent com-
plex consisting of cathepsin L associated with an Ii
fragment was isolated from human kidney [117]. This
fragment proved to be a potent inhibitor of cathepsin
L and originated from the alternatively spliced exon
BBAMCR 14817 5-2-02
P. Stumptner-Cuvelette, P. Benaroch / Biochimica et Biophysica Acta 1542 (2002) 1^136
6B of Iip41, one of the minor isoforms of Ii [118].
The in vivo signi¢cance of this interaction was re-
cently revealed by analyzing bone marrow derived
APCs from mutant mice that express either Iip31
or Iip41. Interestingly, Iip41 proved necessary for
the expression and activity of mature cathepsin L
indicating a chaperone function [119]. Modulation
of cathepsin L activity by Iip41 would in£uence the
production of functional MHC II, since this enzyme
can convert KLp10 into KLCLIP in thymic epithelial
cells [115]. Ii could further protect H2-DM from deg-
radation, since its absence in splenocytes and mature
DCs from Ii de¢cient mice resulted in strongly re-
duced levels of H2-DM [120]. This suggests that Ii
could regulate peptide loading through its protective
activity on H2-DM. Interestingly, immature DCs
from Ii de¢cient mice contained normal levels of
H2-DM [120], indicating that the changes induced
within the endocytic pathway during DC maturation
led to the exposure of H2-DM to a protease activity.
How Ii would protect H2-DM and which enzyme(s)
are involved remains to be established. Defects ob-
served in the CD4 T cell repertoire of Ii de¢cient
mice may thus re£ect not only aberrant MHC II
tra⁄cking, but also compromised H2-DM function-
ing.
4.3. Remaining in the endocytic pathway
According to the emerging scenario, Ii associated
to newly synthesized KL chains would be degraded in
a stepwise manner while the complexes progress
deeper in the endocytic pathway to reach the loading
compartments, where HLA-DM catalyzes the ex-
change of CLIP for antigenic peptides. The exact
nature of these compartments has been a matter of
intense investigations, but confusing conclusions (re-
viewed in [121]). It should be noted that tra⁄cking of
MHC II in the endocytic pathway appears highly
dynamic and the classi¢cation of compartments is
thus by de¢nition arti¢cial. It is clear nevertheless
that peptide loading takes place in late endocytic
compartments rich in MHC II (termed MIIC), which
contain HLA-DM and certain proteases [121]. Ii and
its fragments, Iip22 and Iip10, would drive associ-
ated KL complexes to these MIICs.
The use of protease inhibitors, such as leupeptin,
proved to be a great help; ¢rstly, to demonstrate that
Ii carries signals for retention within the endocytic
pathway [122,123], secondly, to characterize and lo-
calize Ii degradation intermediates [83,124^126], and
thirdly, to establish that degradation of Ii has to be
complete in order to accomplish peptide loading and
cell surface expression of mature MHC II [125,127].
Indeed, exposure to leupeptin led to a selective and
dramatic accumulation of MHC II and Iip10 frag-
ment in dense lysosomes [123^125]. The Iip10 frag-
ment contains an intact cytoplasmic tail, carrying in
all likelihood the retention signal constituted by the
two di-leucine based motifs. In addition, results from
a study performed with melanoma cells suggest that
¢nal degradation of Ii and peptide loading could
take place in distinct compartments, but probably
have to be coordinated in time [128].
4.4. Modi¢cations of the endocytic pathway
Evidence has accumulated that expression of Ii
chain modi¢es the morphology of endocytic com-
partments. Transfection of Ii chain into MHC II
negative cell lines resulted in its accumulation in
large vacuolar compartments containing late endoso-
mal markers [10,58]. In the presence of MHC II
morphological changes depended on overexpression
of Ii chain relative to MHC II [84]. Inhibition of Ii
degradation by various means created similar mod-
i¢cations of the endocytic pathway. Exposure of hu-
man EBV transformed B cells to concanamycin B, a
highly selective inhibitor of the vacuolar H (v)-
ATPase responsible for acidi¢cation of endosomal
compartments, resulted in inhibition of Ii chain deg-
radation and striking accumulation of KLIi com-
plexes in large and electron-lucent multivesicular
bodies (MVB) [80]. Exposure of MelJuso cells to
the protease inhibitor leupeptin caused an about
2-fold increase in total number of MVB enriched in
Ii chain and Ii fragments [126]. In a MHC II express-
ing cell line de¢cient for HLA-DM expression, inef-
¢cient Ii chain proteolysis was observed, resulting in
the accumulation of KLIi complexes in large, acidic
intracellular compartments possessing unusual large
vacuoles with internal membranes and vesicles [129].
In addition, transfection of HLA-DRK and L chains
into embryonal kidney cells appeared su⁄cient to
induce formation of typical MIIC compartments
[130]. Therefore, Ii alone or together with MHC II
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chains seems able to induce vesicle biogenesis within
the endocytic pathway.
Interestingly, Ii also seems to delay tra⁄c within
the endocytic pathway. Prevention of Ii degradation
induced a delay in transport of endocytosed material
from early structures to late endosomes [126] but this
could have resulted from a general e¡ect of protease
inhibitors. However, expression of K, L and wild type
Ii in a ¢broblast cell line led to a delayed transport of
internalized peroxidase from early to late endosomes
[131]. Similar observations were made in transfected
COS cells [84]. In contrast, use of an Ii mutant lack-
ing the cytoplasmic tail showed no e¡ect, suggesting
that Ii cytoplasmic tail could favor peptide loading
by delaying access to lysosomes [131].
Therefore, Ii not only targets KLIi complexes from
the TGN to EE and then retains them in deeper
endocytic compartments, but may also modify gen-
eral tra⁄cking and morphology within this pathway.
Ultimately, Ii would control the departure of MHC
II from MIIC, since its total degradation is required
for expression of MHC II at the cell surface [125].
5. Regulation of Ii functioning: the particular case of
dendritic cells
Until a few years ago many cell biological studies
on MHC II presentation had been achieved in EBV
transformed B cells, a constantly activated cell type.
This may have biased our view of the phenomenon,
since MHC II presentation by primary cells may re-
quire induction by various means. Depending on the
APC and the stimulus considered, these events might
be di¡erently regulated in situations such as DC
maturation, antigen receptor mediated activation of
B lymphocytes and exposure of monocytes/macro-
phages to in£ammatory cytokines. The best docu-
mented examples of tight regulation of MHC II
presentation come from studies on mouse and hu-
man DCs, which reveal interesting di¡erences [132,
133].
In human immature DCs, the majority of newly
synthesized MHC II are ¢rst delivered to the cell
surface in association with Ii and then rapidly inter-
nalized in the endocytic pathway [81]. There, degra-
dation of Ii occurs in a cathepsin S dependent man-
ner allowing MHC II to load peptides and access the
cell surface [134]. KL-Peptide complexes possess a
half-life of about 10 h and are constantly and rapidly
internalized and recycled [135]. Induction of DC
maturation by in£ammatory stimuli such as LPS,
IL1L or TNFK results in many changes. A boost of
MHC II synthesis is observed within 2 h [135], the
activity of cathepsins S and B augments and the en-
dosomal pH decreases [136]. This increases antigen
degradation, SDS-stable dimer formation [136] and
MHC II surface expression, while DC endocytic ca-
pacity is severely reduced [137]. Finally, the half-life
of MHC II complexes increases by 10-fold favoring
potential interaction with the antigen receptor of
CD4 T cells at the plasma membrane [135]. In-
terestingly, exposure of immature DCs to IL10, an
anti-in£ammatory cytokine, diminished the levels
of cathepsins S and B and prevented IL1L induced
upregulation of these enzymes. This resulted in de-
layed MHC II maturation, ine⁄cient antigen degra-
dation and therefore in poor antigen presentation by
MHC II [136], as initially observed in Langerhans
cells [138]. Thus, when DCs are exposed to in£am-
matory stimuli, their capacity to induce an immune
response would heavily depend on their cytokine en-
vironment.
More studies have been performed on MHC II
tra⁄cking in mouse DCs, generating sometimes con-
£icting conclusions resulting in part from the di¡er-
ent setup used (various origins of the DCs expressing
di¡erent MHC II allotypes). An attempt to summa-
rize these results in a highly simpli¢ed manner is
presented in Fig. 2. In immature mouse DCs newly
synthesized MHC II were mainly observed in lysoso-
mal compartments [139]. An elegant study using
C4H3, a monoclonal antibody speci¢c for I-Ak asso-
ciated with a peptide derived from the hen egg lyso-
zyme (HEL) antigen, indicated that antigen presenta-
tion by MHC II did not take place in immature DCs,
although internalized antigen and MHC II could ex-
tensively co-localize [140]. Exposure to in£ammatory
mediators such as LPS, CD40 ligand or TNFK in-
duced a dramatic appearance of the I-Ak^HEL com-
plexes at the cell surface [140,141]. DC maturation
was accompanied by a boost of MHC II synthesis
[142]. KL-Peptide complexes acquired a longer half-
life [139] and were transported together with costim-
ulatory molecules via peripheral non-lysosomal
vesicles to the cell surface [139,141]. There, they
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stayed in clusters with co-stimulatory molecules and
MHC I, potentially facilitating the formation of an
immunological synapse between DCs and T cells
[141]. These changes would result mostly from mod-
i¢cations in the degradation kinetics of Ii. From their
study performed in H-2b mice Pierre and Mellman
proposed that Ii degradation is hampered in imma-
ture DCs and its p10 fragment remains associated
with MHC II thus retained in lysosomal com-
partments [143]. This would result from cystatin C
mediated inhibition of cathepsin S, the enzyme
known to convert KLp10 into KLCLIP in DCs.
Upon maturation, cystatin C activity decreases al-
lowing ¢nal steps of Ii degradation and MHC II
maturation to occur.
Cystatin C mediated inhibition of cathepsin S re-
lies on a highly conserved region that binds the ac-
tive site of the enzyme [144]. Cystatin C can also
inhibit other cathepsins present in the endocytic
pathway and contains a second inhibitory site specif-
ic for AEP [145]. Thus, expression of cystatin C in
immature DCs could compromise the stepwise deg-
radation of Ii and the peptide loading process. How-
ever, results obtained in DCs from cathepsin S de¢-
cient mice suggest that the proposed model is
incomplete and that other mechanism(s) might be
at work. Firstly, KLIip10 complexes were found not
only in endocytic compartments but also at the cell
surface [111^113], suggesting that retention by Iip10
was not complete. Secondly, when originating from
an H2k;q;s or u background, normal maturation of I-A
molecules occurred (see [106]), indicating that ca-
thepsin S activity is dispensable. MHC II complexes
appeared to behave normally in DCs from Ii knock-
out mice (H-2k): they accumulated in MIIC of im-
mature DCs, while they were exported to the plasma
membrane during DC maturation. In addition, pre-
sentation of putative Ii dependent antigen by MHC
II was not a¡ected by the lack of Ii, suggesting that
MHC II transport and peptide loading can occur in
DCs in an Ii independent manner [39]. A recent
study supports this conclusion and further indicates
that mouse DCs may behave more like their human
counterparts than initially thought [146]. Indeed, in
immature DCs MHC II^peptide complexes had a
short half-life as they were found to be re-endocy-
tosed and degraded at a much faster rate than in
mature DCs (see Fig. 2). Degradation of the Ii chain,
Fig. 2. Simpli¢ed model of MHC II tra⁄cking in developing murine DCs. Three stages of DCs are presented. Immature DCs can be
activated by in£ammatory stimuli to become ‘intermediate’ DCs after a few hours, which di¡erentiate into mature DCs after 24 h.
The width of the arrows indicates the relative £ow of molecules (MHC II or antigen). Faded symbols at the mature stage re£ect the
reduction of MHC II synthesis and tra⁄cking. Ag stands for antigen, KLpep for MHC II complexes loaded with peptide. See text for
detailed explanation.
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peptide loading and access of mature MHC II to the
cell surface occurred at similar rates in immature and
activated DCs [146]. Therefore, antigen presentation
by DCs would be mainly controlled by the rate of re-
endocytosis of MHC II^peptide complexes rather
than by Ii chain degradation.
6. Additional function and future directions
Analysis of T independent responses in Ii de¢cient
mice revealed that the development of their B lym-
phocytes was blocked at the immature stage. This
blockage was independent of MHC II expression,
since it was not observed in mice lacking MHC II
L chain nor in mice de¢cient for the transactivator
CIITA and correlated with levels of Ii [147]. Further-
more, expression of a truncated form of Ii (Ii1^82)
essentially lacking the luminal domain was su⁄cient
to drive di¡erentiation of immature B cells in a pro-
cess independent of Ii chaperone activity (I. Shachar
and D. Matza, personal communication). Ii induces
B cell maturation by activating a transcription path-
way dependent on the transcription factor NF-UB
[148]. More work is required to understand how Ii
exerts this function.
Apart from its role on MHC II correct functioning
and despite its small size, Ii represents a model pro-
tein of great interest for cell biological studies regard-
ing chaperone function, intracellular protein sorting
and degradation events. Many open questions still
remain. The regulation of Ii and antigen degradation
represents a ¢eld of intense investigations. The im-
portant role of cystatin C and cathepsin S in these
processes is getting established. Note that cathepsin S
was recently shown to regulate the activity of cathep-
sin L and the turnover of GILT (a thiol reductase
involved in the ¢rst steps of antigenic degradation in
endosomes [149]) in B lymphocytes [150]. The sorting
machinery involved in Ii mediated targeting of MHC
II complexes at the TGN level has yet to be identi-
¢ed. Similarly, the molecular basis of Ii in£uence on
the biogenesis of multilamellar and vesicular com-
partments rich in MHC II remains elusive. No doubt
investigations on the molecular basis of the functions
of Ii will continue to produce information of great
interest.
7. Note added in proof
A new function of the Ii chain has been recently
documented, Ii would play a role in targeting CD1d
molecules to the endocytic pathway (Jayawardena-
Wolf et al., 2001 Immunity, 15 in press).
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